A clinical trial record referencing vasopressin was updated on October 9, 2026. The trial, titled "BLinatumomab and iNKT in Relapsed B-Cell ALL," is registered under identifier NCT07869368. It is listed as a Phase 1 study. According to the record, the trial status is currently "not yet recruiting." No participants have been enrolled at this stage, and no results have been posted. The registration does not include outcome data, efficacy claims, or safety findings at this time. This update reflects only the administrative status of the trial as recorded on the given date. Readers should note that further changes to recruitment status, timelines, or trial design may occur as the study progresses. For additional context on vasopressin, including its approved regulatory status and general background, readers can consult the compound overview.
Phase 1 Trial Involving Vasopressin Listed, Not Yet Recruiting
See the full vasopressin overview
Source: https://clinicaltrials.gov/study/NCT07869368